Paris-based Sanofi will acquire all outstanding shares of Waltham, Mass.-based Bioverativ for approximately $11.6 billion.
The boards of directors of Sanofi and Bioverativ unanimously approved the deal. Bioverativ, a biopharmaceutical company developing therapies for hemophilia and other rare blood disorders, generated $847 million in sales in 2016.
Bioverativ's products Eloctate and Alprolix were the first major advancements in hemophilia therapies in nearly two decades when launched. Bioverativ markets Eloctate and Alprolix in the U.S., Japan, Canada and Australia, and plans to market them in additional geographies.
More articles on supply chain:
Celgene to acquire Juno Therapeutics for $9B, betting on a future for CAR-T therapies
Kick-start your supply chain in 2018: 3 New Year's Resolutions
Recognize 5 types of supply chain leaders in your hospital